Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
CA-125 Antigen | 51 | 2024 | 280 | 5.440 |
Why?
|
Ovarian Neoplasms | 87 | 2024 | 4877 | 4.590 |
Why?
|
Early Detection of Cancer | 39 | 2024 | 3200 | 3.100 |
Why?
|
Mass Screening | 34 | 2024 | 5428 | 1.100 |
Why?
|
Membrane Proteins | 13 | 2020 | 7852 | 0.790 |
Why?
|
Neoplasms, Glandular and Epithelial | 8 | 2017 | 487 | 0.790 |
Why?
|
Ultrasonography | 18 | 2024 | 5970 | 0.580 |
Why?
|
Blood Proteins | 5 | 2016 | 1180 | 0.570 |
Why?
|
Epididymal Secretory Proteins | 5 | 2011 | 12 | 0.550 |
Why?
|
Algorithms | 23 | 2020 | 14025 | 0.520 |
Why?
|
Sensitivity and Specificity | 30 | 2024 | 14665 | 0.500 |
Why?
|
Mesothelioma | 8 | 2014 | 807 | 0.480 |
Why?
|
GPI-Linked Proteins | 8 | 2014 | 468 | 0.460 |
Why?
|
Proteomics | 8 | 2022 | 3843 | 0.420 |
Why?
|
Pelvic Neoplasms | 3 | 2012 | 247 | 0.420 |
Why?
|
Fallopian Tube Neoplasms | 5 | 2017 | 328 | 0.410 |
Why?
|
Neoplasms | 10 | 2022 | 22158 | 0.350 |
Why?
|
Ovary | 4 | 2020 | 959 | 0.340 |
Why?
|
Endometrial Neoplasms | 6 | 2024 | 1365 | 0.330 |
Why?
|
Predictive Value of Tests | 18 | 2024 | 15262 | 0.330 |
Why?
|
Postmenopause | 16 | 2018 | 2513 | 0.320 |
Why?
|
Risk Assessment | 11 | 2020 | 23981 | 0.320 |
Why?
|
Specimen Handling | 1 | 2013 | 703 | 0.320 |
Why?
|
Mass Spectrometry | 8 | 2022 | 2193 | 0.320 |
Why?
|
beta-Defensins | 5 | 2011 | 59 | 0.300 |
Why?
|
Genes, BRCA2 | 3 | 2014 | 601 | 0.300 |
Why?
|
BRCA2 Protein | 4 | 2022 | 804 | 0.290 |
Why?
|
Female | 114 | 2024 | 392485 | 0.290 |
Why?
|
ROC Curve | 13 | 2024 | 3572 | 0.290 |
Why?
|
Genes, BRCA1 | 3 | 2014 | 764 | 0.290 |
Why?
|
Autoantibodies | 5 | 2024 | 2123 | 0.270 |
Why?
|
Peritoneal Neoplasms | 3 | 2012 | 711 | 0.270 |
Why?
|
DNA Methylation | 1 | 2020 | 4383 | 0.270 |
Why?
|
Humans | 144 | 2024 | 761326 | 0.260 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13333 | 0.260 |
Why?
|
BRCA1 Protein | 4 | 2022 | 1155 | 0.260 |
Why?
|
Warfarin | 5 | 2001 | 1483 | 0.250 |
Why?
|
Middle Aged | 76 | 2024 | 220774 | 0.250 |
Why?
|
Aged | 64 | 2024 | 169179 | 0.250 |
Why?
|
Macrophage Colony-Stimulating Factor | 2 | 2007 | 186 | 0.250 |
Why?
|
Neoplasm Staging | 16 | 2019 | 11098 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2016 | 8527 | 0.230 |
Why?
|
Pleural Effusion, Malignant | 3 | 2014 | 106 | 0.230 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 4 | 2024 | 136 | 0.220 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2003 | 56 | 0.220 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3611 | 0.210 |
Why?
|
Genital Neoplasms, Female | 3 | 2024 | 532 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 3 | 2024 | 20555 | 0.190 |
Why?
|
Osteopontin | 5 | 2011 | 301 | 0.190 |
Why?
|
Prospective Studies | 24 | 2023 | 54405 | 0.180 |
Why?
|
Adenocarcinoma, Clear Cell | 3 | 2019 | 217 | 0.180 |
Why?
|
Mucin-1 | 2 | 2007 | 539 | 0.180 |
Why?
|
Models, Statistical | 2 | 2014 | 5078 | 0.180 |
Why?
|
Models, Biological | 3 | 2014 | 9468 | 0.180 |
Why?
|
International Normalized Ratio | 2 | 2001 | 382 | 0.180 |
Why?
|
Breast Neoplasms | 8 | 2022 | 21009 | 0.180 |
Why?
|
Heterozygote | 2 | 2020 | 2803 | 0.160 |
Why?
|
Sialoglycoproteins | 3 | 2006 | 315 | 0.160 |
Why?
|
Anticoagulants | 5 | 2001 | 4813 | 0.150 |
Why?
|
Analgesics, Non-Narcotic | 2 | 1998 | 370 | 0.150 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2019 | 517 | 0.150 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2019 | 478 | 0.150 |
Why?
|
Chromatography, Affinity | 2 | 2016 | 532 | 0.150 |
Why?
|
Membrane Glycoproteins | 4 | 2010 | 3701 | 0.140 |
Why?
|
Acetaminophen | 2 | 1998 | 554 | 0.140 |
Why?
|
Adult | 40 | 2024 | 221122 | 0.140 |
Why?
|
Longitudinal Studies | 6 | 2021 | 14597 | 0.140 |
Why?
|
Sample Size | 2 | 2013 | 839 | 0.140 |
Why?
|
Proteins | 7 | 2023 | 6034 | 0.140 |
Why?
|
Aged, 80 and over | 23 | 2021 | 58946 | 0.140 |
Why?
|
Carcinoma | 4 | 2023 | 2328 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2023 | 946 | 0.140 |
Why?
|
Pleural Neoplasms | 2 | 2014 | 609 | 0.140 |
Why?
|
Blood Specimen Collection | 2 | 2015 | 238 | 0.130 |
Why?
|
Vitamin K | 1 | 1998 | 318 | 0.130 |
Why?
|
Research Design | 3 | 2013 | 6178 | 0.130 |
Why?
|
Menopause | 3 | 2017 | 1646 | 0.120 |
Why?
|
Follow-Up Studies | 20 | 2021 | 39108 | 0.120 |
Why?
|
State Medicine | 3 | 2022 | 216 | 0.120 |
Why?
|
Registries | 4 | 2021 | 8223 | 0.120 |
Why?
|
Prostate | 1 | 2022 | 1770 | 0.110 |
Why?
|
Case-Control Studies | 12 | 2024 | 22124 | 0.110 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2014 | 101 | 0.110 |
Why?
|
Contraceptives, Oral | 2 | 2017 | 554 | 0.110 |
Why?
|
Prognosis | 17 | 2020 | 29588 | 0.100 |
Why?
|
Schools | 1 | 2021 | 1488 | 0.100 |
Why?
|
Genital Diseases, Female | 2 | 2011 | 192 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 8 | 2024 | 3806 | 0.100 |
Why?
|
Risk Factors | 24 | 2018 | 74152 | 0.100 |
Why?
|
Immunoassay | 3 | 2010 | 746 | 0.100 |
Why?
|
Skull Neoplasms | 2 | 1992 | 173 | 0.100 |
Why?
|
Reproducibility of Results | 9 | 2018 | 20092 | 0.100 |
Why?
|
Long Interspersed Nucleotide Elements | 2 | 2023 | 330 | 0.090 |
Why?
|
Chondrosarcoma | 2 | 1992 | 296 | 0.090 |
Why?
|
Extracellular Matrix Proteins | 1 | 2014 | 828 | 0.090 |
Why?
|
Early Diagnosis | 2 | 2007 | 1184 | 0.090 |
Why?
|
Endometrial Hyperplasia | 1 | 2010 | 97 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 2911 | 0.080 |
Why?
|
Vitreous Hemorrhage | 1 | 1989 | 48 | 0.080 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 983 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2004 | 3161 | 0.080 |
Why?
|
Cohort Studies | 11 | 2024 | 41440 | 0.080 |
Why?
|
Proteome | 3 | 2015 | 1863 | 0.080 |
Why?
|
Ovariectomy | 3 | 2022 | 614 | 0.080 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 75 | 0.080 |
Why?
|
Asbestos | 1 | 2010 | 251 | 0.080 |
Why?
|
Area Under Curve | 3 | 2011 | 1633 | 0.070 |
Why?
|
Limit of Detection | 3 | 2013 | 272 | 0.070 |
Why?
|
Mutation | 5 | 2022 | 30044 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2004 | 4246 | 0.070 |
Why?
|
Patient Selection | 2 | 2011 | 4244 | 0.070 |
Why?
|
Quality Assurance, Health Care | 1 | 2018 | 2170 | 0.070 |
Why?
|
Logistic Models | 5 | 2008 | 13251 | 0.070 |
Why?
|
Blood Transfusion | 1 | 1994 | 1299 | 0.070 |
Why?
|
Premenopause | 1 | 2011 | 1039 | 0.070 |
Why?
|
Incidence | 5 | 2022 | 21336 | 0.070 |
Why?
|
Perception | 1 | 2013 | 1197 | 0.070 |
Why?
|
Eosinophil-Derived Neurotoxin | 1 | 2006 | 13 | 0.070 |
Why?
|
Vitrectomy | 1 | 1989 | 392 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 6 | 2022 | 17872 | 0.070 |
Why?
|
Chordoma | 1 | 1989 | 346 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2021 | 12450 | 0.060 |
Why?
|
Pleura | 1 | 2007 | 244 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1994 | 2199 | 0.060 |
Why?
|
Serine Endopeptidases | 3 | 2001 | 1021 | 0.060 |
Why?
|
Prolactin | 1 | 2007 | 625 | 0.060 |
Why?
|
Life Style | 1 | 2017 | 3915 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 10203 | 0.060 |
Why?
|
Antigens, Neoplasm | 3 | 2014 | 1994 | 0.060 |
Why?
|
Risk | 2 | 2020 | 9605 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 59196 | 0.060 |
Why?
|
Lymphatic Metastasis | 3 | 2010 | 2914 | 0.060 |
Why?
|
United States Food and Drug Administration | 2 | 2009 | 1665 | 0.060 |
Why?
|
Discriminant Analysis | 1 | 2004 | 222 | 0.060 |
Why?
|
Health Personnel | 1 | 2018 | 3335 | 0.060 |
Why?
|
Selection Bias | 1 | 2006 | 359 | 0.060 |
Why?
|
Diagnostic Tests, Routine | 1 | 2009 | 787 | 0.060 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1703 | 0.050 |
Why?
|
Salpingectomy | 1 | 2022 | 45 | 0.050 |
Why?
|
Vagina | 3 | 2017 | 838 | 0.050 |
Why?
|
Epidemiologic Research Design | 1 | 2006 | 368 | 0.050 |
Why?
|
Fallopian Tubes | 1 | 2023 | 177 | 0.050 |
Why?
|
Haptoglobins | 1 | 2003 | 167 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2004 | 3777 | 0.050 |
Why?
|
Vitamin K 1 | 1 | 2001 | 47 | 0.050 |
Why?
|
Midwestern United States | 1 | 2021 | 70 | 0.050 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2015 | 297 | 0.050 |
Why?
|
Radioimmunoassay | 2 | 1991 | 866 | 0.040 |
Why?
|
Time Factors | 9 | 2013 | 39974 | 0.040 |
Why?
|
Half-Life | 1 | 2001 | 652 | 0.040 |
Why?
|
Genomics | 1 | 2016 | 5817 | 0.040 |
Why?
|
Diabetic Retinopathy | 1 | 1989 | 1274 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 621 | 0.040 |
Why?
|
Retrospective Studies | 9 | 2019 | 80575 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12059 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 397 | 0.040 |
Why?
|
Male | 22 | 2022 | 360621 | 0.040 |
Why?
|
Hemorrhage | 3 | 2001 | 3425 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2012 | 7999 | 0.040 |
Why?
|
Receptors, Cell Surface | 1 | 2008 | 2820 | 0.040 |
Why?
|
Pilot Projects | 4 | 2020 | 8632 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 4014 | 0.040 |
Why?
|
Age Factors | 5 | 2017 | 18401 | 0.040 |
Why?
|
Anxiety | 1 | 2013 | 4571 | 0.040 |
Why?
|
Cooperative Behavior | 2 | 2017 | 1504 | 0.040 |
Why?
|
Peptides | 3 | 2022 | 4342 | 0.040 |
Why?
|
Germ Cells | 1 | 2022 | 634 | 0.040 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 462 | 0.040 |
Why?
|
Antifibrinolytic Agents | 1 | 2001 | 292 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2014 | 12972 | 0.040 |
Why?
|
Neoplasm Invasiveness | 3 | 2014 | 3588 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 1600 | 0.040 |
Why?
|
Immunohistochemistry | 6 | 2014 | 11070 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2011 | 12329 | 0.040 |
Why?
|
Adolescent | 8 | 2021 | 88305 | 0.040 |
Why?
|
Drug Interactions | 2 | 1998 | 1415 | 0.030 |
Why?
|
Sterilization, Tubal | 1 | 2017 | 75 | 0.030 |
Why?
|
Survival Rate | 6 | 2012 | 12710 | 0.030 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2016 | 32 | 0.030 |
Why?
|
Paclitaxel | 1 | 2004 | 1732 | 0.030 |
Why?
|
Combined Modality Therapy | 4 | 2003 | 8526 | 0.030 |
Why?
|
Population Surveillance | 2 | 2022 | 2603 | 0.030 |
Why?
|
Pleural Effusion | 1 | 1999 | 342 | 0.030 |
Why?
|
Peroxidase | 2 | 1997 | 610 | 0.030 |
Why?
|
S-Phase Kinase-Associated Proteins | 1 | 2016 | 90 | 0.030 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2016 | 119 | 0.030 |
Why?
|
Signal Transduction | 2 | 2016 | 23427 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 3531 | 0.030 |
Why?
|
Self Report | 2 | 2018 | 3724 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2020 | 491 | 0.030 |
Why?
|
p21-Activated Kinases | 1 | 2016 | 128 | 0.030 |
Why?
|
Mediastinal Neoplasms | 2 | 1988 | 402 | 0.030 |
Why?
|
Biological Specimen Banks | 2 | 2011 | 783 | 0.030 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 1997 | 288 | 0.030 |
Why?
|
Autoantigens | 2 | 1997 | 892 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2004 | 9275 | 0.030 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2016 | 385 | 0.030 |
Why?
|
Probability | 2 | 2001 | 2478 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 11735 | 0.030 |
Why?
|
London | 1 | 2014 | 234 | 0.030 |
Why?
|
Mouth Neoplasms | 2 | 1989 | 596 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2000 | 791 | 0.030 |
Why?
|
Connective Tissue Diseases | 1 | 1997 | 285 | 0.030 |
Why?
|
Menarche | 1 | 2017 | 532 | 0.030 |
Why?
|
Biological Products | 1 | 2003 | 913 | 0.030 |
Why?
|
Markov Chains | 1 | 2017 | 965 | 0.030 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 523 | 0.030 |
Why?
|
Blood Transfusion, Autologous | 1 | 1994 | 130 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1246 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2016 | 535 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2020 | 5247 | 0.030 |
Why?
|
Endosonography | 1 | 2017 | 610 | 0.030 |
Why?
|
Prostatic Neoplasms | 2 | 2011 | 11116 | 0.030 |
Why?
|
Radiation Tolerance | 2 | 1992 | 479 | 0.030 |
Why?
|
Radiation Injuries | 2 | 1992 | 1189 | 0.030 |
Why?
|
Colorectal Neoplasms | 2 | 2011 | 6901 | 0.030 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 507 | 0.030 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2016 | 654 | 0.030 |
Why?
|
Hematocrit | 1 | 1994 | 625 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 9414 | 0.030 |
Why?
|
Sweden | 1 | 1995 | 1379 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 5 | 1993 | 882 | 0.030 |
Why?
|
False Positive Reactions | 2 | 2009 | 956 | 0.030 |
Why?
|
Gene Library | 1 | 2015 | 1059 | 0.030 |
Why?
|
United States | 8 | 2017 | 72317 | 0.020 |
Why?
|
Amino Acid Sequence | 3 | 2013 | 13446 | 0.020 |
Why?
|
Chondroma | 1 | 1992 | 53 | 0.020 |
Why?
|
Family Characteristics | 1 | 2017 | 1003 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 898 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2002 | 2319 | 0.020 |
Why?
|
Hysterectomy | 1 | 2017 | 857 | 0.020 |
Why?
|
Cranial Nerves | 1 | 1992 | 98 | 0.020 |
Why?
|
Thromboembolism | 1 | 1998 | 996 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 2016 | 1387 | 0.020 |
Why?
|
Automation, Laboratory | 1 | 2011 | 103 | 0.020 |
Why?
|
Calcium-Binding Proteins | 1 | 2016 | 1069 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 1 | 1992 | 228 | 0.020 |
Why?
|
beta 2-Microglobulin | 1 | 2012 | 329 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2013 | 17640 | 0.020 |
Why?
|
Transferrin | 1 | 2012 | 284 | 0.020 |
Why?
|
Immunoglobulin G | 2 | 2021 | 4550 | 0.020 |
Why?
|
Biopsy | 3 | 2014 | 6768 | 0.020 |
Why?
|
Apolipoprotein A-I | 1 | 2012 | 299 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1722 | 0.020 |
Why?
|
Prealbumin | 1 | 2012 | 222 | 0.020 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 934 | 0.020 |
Why?
|
Infertility | 1 | 2017 | 654 | 0.020 |
Why?
|
Medical Oncology | 1 | 2002 | 2321 | 0.020 |
Why?
|
Research Personnel | 1 | 2015 | 588 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2015 | 803 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3155 | 0.020 |
Why?
|
Data Interpretation, Statistical | 2 | 2010 | 2691 | 0.020 |
Why?
|
Serum | 1 | 2011 | 210 | 0.020 |
Why?
|
Patient Compliance | 1 | 2020 | 2690 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2009 | 162 | 0.020 |
Why?
|
Reference Standards | 1 | 2013 | 1004 | 0.020 |
Why?
|
DNA, Complementary | 2 | 2004 | 1992 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2011 | 878 | 0.020 |
Why?
|
Glomerulonephritis | 1 | 1991 | 336 | 0.020 |
Why?
|
Hospitals, Community | 1 | 1991 | 365 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2000 | 2775 | 0.020 |
Why?
|
Protein Kinases | 1 | 2016 | 1607 | 0.020 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2011 | 629 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 1989 | 321 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2010 | 337 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 1998 | 2469 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2016 | 1249 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5492 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2015 | 1738 | 0.020 |
Why?
|
Pentobarbital | 1 | 1988 | 152 | 0.020 |
Why?
|
Adnexa Uteri | 1 | 2007 | 40 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2712 | 0.020 |
Why?
|
Decision Making | 1 | 2002 | 3929 | 0.020 |
Why?
|
Hip Prosthesis | 1 | 1994 | 921 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 1989 | 183 | 0.020 |
Why?
|
Receptor, erbB-2 | 2 | 2016 | 2556 | 0.020 |
Why?
|
Plasma | 1 | 2011 | 586 | 0.020 |
Why?
|
Treatment Outcome | 5 | 2023 | 64645 | 0.020 |
Why?
|
Intensive Care Units | 2 | 1991 | 3744 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 691 | 0.020 |
Why?
|
Blood Chemical Analysis | 1 | 2009 | 437 | 0.020 |
Why?
|
Cattle | 1 | 2013 | 3849 | 0.020 |
Why?
|
Immunotherapy | 1 | 2003 | 4649 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2016 | 2445 | 0.020 |
Why?
|
Technology Assessment, Biomedical | 1 | 2009 | 307 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2859 | 0.020 |
Why?
|
Information Dissemination | 1 | 2015 | 1127 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 1991 | 1336 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 283 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 4567 | 0.020 |
Why?
|
Ultrasonography, Mammary | 1 | 2007 | 239 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2011 | 1186 | 0.020 |
Why?
|
Rabbits | 1 | 2011 | 4779 | 0.020 |
Why?
|
Prevalence | 2 | 2014 | 15719 | 0.020 |
Why?
|
Patient Care Planning | 1 | 1990 | 908 | 0.020 |
Why?
|
Actinomycetales | 1 | 1984 | 33 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2010 | 1257 | 0.010 |
Why?
|
Chest Pain | 1 | 1991 | 1090 | 0.010 |
Why?
|
Cytoplasm | 2 | 2004 | 1511 | 0.010 |
Why?
|
Myeloblastin | 2 | 1997 | 101 | 0.010 |
Why?
|
Soil Microbiology | 1 | 1984 | 88 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 2002 | 6128 | 0.010 |
Why?
|
Radiotherapy Dosage | 4 | 1993 | 2898 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 2 | 1989 | 4022 | 0.010 |
Why?
|
Protons | 1 | 1989 | 1115 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2007 | 2265 | 0.010 |
Why?
|
RNA, Messenger | 3 | 2003 | 12787 | 0.010 |
Why?
|
Neoplasms, Experimental | 1 | 1988 | 1229 | 0.010 |
Why?
|
Infusions, Parenteral | 1 | 2003 | 398 | 0.010 |
Why?
|
Computational Biology | 1 | 2015 | 3512 | 0.010 |
Why?
|
Carcinoma, Endometrioid | 1 | 2006 | 276 | 0.010 |
Why?
|
Brain Ischemia | 1 | 1996 | 3048 | 0.010 |
Why?
|
Glycosylation | 1 | 2006 | 1098 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 2003 | 412 | 0.010 |
Why?
|
Linear Models | 2 | 2009 | 5871 | 0.010 |
Why?
|
Reference Values | 2 | 2001 | 4921 | 0.010 |
Why?
|
Biotin | 1 | 2003 | 254 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2012 | 2221 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2003 | 1306 | 0.010 |
Why?
|
Computers | 1 | 1984 | 596 | 0.010 |
Why?
|
Dimerization | 1 | 2003 | 891 | 0.010 |
Why?
|
Anorexia Nervosa | 1 | 1991 | 1361 | 0.010 |
Why?
|
Family Health | 1 | 2006 | 1257 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2007 | 2927 | 0.010 |
Why?
|
Organoplatinum Compounds | 1 | 2003 | 407 | 0.010 |
Why?
|
Animals | 6 | 2016 | 168388 | 0.010 |
Why?
|
Vision Disorders | 1 | 1989 | 1088 | 0.010 |
Why?
|
Osteoporosis | 1 | 1991 | 1605 | 0.010 |
Why?
|
Postoperative Care | 1 | 1987 | 1471 | 0.010 |
Why?
|
Drugs, Investigational | 1 | 2003 | 212 | 0.010 |
Why?
|
Survival Analysis | 2 | 2007 | 10075 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1988 | 1374 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 1988 | 1378 | 0.010 |
Why?
|
Length of Stay | 2 | 1991 | 6422 | 0.010 |
Why?
|
Computer Systems | 1 | 2001 | 471 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26108 | 0.010 |
Why?
|
Taxoids | 1 | 2003 | 666 | 0.010 |
Why?
|
Visual Acuity | 1 | 1989 | 2671 | 0.010 |
Why?
|
Cell Survival | 1 | 1989 | 5792 | 0.010 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2013 | 2241 | 0.010 |
Why?
|
Viscera | 1 | 1999 | 138 | 0.010 |
Why?
|
Mental Health | 1 | 2013 | 3248 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2011 | 5114 | 0.010 |
Why?
|
Software | 1 | 2013 | 4439 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2001 | 749 | 0.010 |
Why?
|
Clinical Enzyme Tests | 1 | 1998 | 115 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 2001 | 1704 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 3 | 1998 | 10764 | 0.010 |
Why?
|
Atrial Fibrillation | 1 | 1996 | 5127 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 1989 | 4509 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1988 | 2879 | 0.010 |
Why?
|
Heart Failure | 1 | 2001 | 11672 | 0.010 |
Why?
|
Anesthesia | 1 | 1988 | 1592 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2011 | 7824 | 0.010 |
Why?
|
Organ Specificity | 1 | 2001 | 1967 | 0.010 |
Why?
|
Postoperative Period | 1 | 2001 | 1813 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1997 | 427 | 0.010 |
Why?
|
Mammography | 1 | 2007 | 2429 | 0.010 |
Why?
|
Blotting, Western | 1 | 2003 | 5034 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 1987 | 2534 | 0.010 |
Why?
|
Odds Ratio | 2 | 1999 | 9639 | 0.010 |
Why?
|
Medical History Taking | 1 | 1999 | 773 | 0.010 |
Why?
|
Age Distribution | 1 | 2001 | 2880 | 0.010 |
Why?
|
Clinical Protocols | 2 | 1991 | 1440 | 0.010 |
Why?
|
Neoplasm Transplantation | 2 | 1989 | 2014 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2008 | 3204 | 0.010 |
Why?
|
Prostatic Hyperplasia | 1 | 1998 | 521 | 0.010 |
Why?
|
Mortality | 2 | 1999 | 2898 | 0.010 |
Why?
|
Pedigree | 1 | 2001 | 4589 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1993 | 5820 | 0.010 |
Why?
|
Germ-Line Mutation | 1 | 2001 | 1858 | 0.010 |
Why?
|
Body Mass Index | 1 | 2011 | 12949 | 0.010 |
Why?
|
Cranial Nerve Injuries | 1 | 1992 | 28 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 1998 | 2853 | 0.010 |
Why?
|
Random Allocation | 1 | 1996 | 2389 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2001 | 6086 | 0.010 |
Why?
|
Recurrence | 1 | 2004 | 8470 | 0.010 |
Why?
|
Radiography, Thoracic | 2 | 1988 | 1303 | 0.010 |
Why?
|
Hospital Bed Capacity, 500 and over | 1 | 1990 | 114 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2003 | 2019 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2002 | 3577 | 0.010 |
Why?
|
Cerebrovascular Disorders | 1 | 1996 | 1475 | 0.010 |
Why?
|
Mitotic Index | 1 | 1989 | 161 | 0.010 |
Why?
|
Menstruation | 1 | 1991 | 307 | 0.010 |
Why?
|
Gene Expression | 1 | 2002 | 7582 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1989 | 815 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1991 | 1626 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1999 | 4908 | 0.000 |
Why?
|
Procarbazine | 1 | 1988 | 172 | 0.000 |
Why?
|
Mechlorethamine | 1 | 1988 | 129 | 0.000 |
Why?
|
Boston | 2 | 1991 | 9333 | 0.000 |
Why?
|
Phosphocreatine | 1 | 1988 | 261 | 0.000 |
Why?
|
Transcription, Genetic | 1 | 2001 | 7597 | 0.000 |
Why?
|
Mice, Inbred C3H | 1 | 1988 | 915 | 0.000 |
Why?
|
Particle Accelerators | 1 | 1987 | 174 | 0.000 |
Why?
|
Fluorescent Antibody Technique | 1 | 1991 | 2468 | 0.000 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 16966 | 0.000 |
Why?
|
Feedback | 1 | 1990 | 791 | 0.000 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1988 | 350 | 0.000 |
Why?
|
Nucleotides | 1 | 1988 | 454 | 0.000 |
Why?
|
Vincristine | 1 | 1988 | 1036 | 0.000 |
Why?
|
Body Temperature | 1 | 1988 | 782 | 0.000 |
Why?
|
Alcohol Drinking | 1 | 1998 | 4027 | 0.000 |
Why?
|
Phosphates | 1 | 1988 | 770 | 0.000 |
Why?
|
Disease Progression | 1 | 2001 | 13500 | 0.000 |
Why?
|
Ecology | 1 | 1984 | 105 | 0.000 |
Why?
|
Spores, Bacterial | 1 | 1984 | 114 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1988 | 2498 | 0.000 |
Why?
|
Child | 2 | 1989 | 80156 | 0.000 |
Why?
|
Prednisone | 1 | 1988 | 1564 | 0.000 |
Why?
|
Mice, Nude | 1 | 1989 | 3603 | 0.000 |
Why?
|
Interviews as Topic | 1 | 1990 | 2696 | 0.000 |
Why?
|
Weight Gain | 1 | 1991 | 2346 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2007 | 36430 | 0.000 |
Why?
|
Diet | 1 | 1998 | 8074 | 0.000 |
Why?
|
Fractures, Bone | 1 | 1991 | 2046 | 0.000 |
Why?
|
Neutrophils | 1 | 1991 | 3765 | 0.000 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1988 | 3768 | 0.000 |
Why?
|
Bone Density | 1 | 1991 | 3551 | 0.000 |
Why?
|
Patient Readmission | 1 | 1991 | 3267 | 0.000 |
Why?
|
Endothelium, Vascular | 1 | 1989 | 4432 | 0.000 |
Why?
|
Cell Line | 1 | 1989 | 15599 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 1989 | 9180 | 0.000 |
Why?
|
Mice | 2 | 1989 | 81474 | 0.000 |
Why?
|